Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
September 06 2016 - 4:05PM
Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP) today
announced that its Board of Directors has declared a quarterly cash
dividend payment on the Company's 10.50% Series E Convertible
Preferred Stock (the "Series E Preferred Stock").
The quarterly dividend on the Series E Preferred
Stock is payable on October 3, 2016 to holders of record at the
close of business on September 16, 2016.
The quarterly dividend payment on the Series E
Preferred Stock will be $0.65625 per share, which is equivalent to
an annualized 10.50% per share, based on the $25.00 per share
stated liquidation preference, accruing from July 1, 2016 through
September 30, 2016. The Series E Preferred Stock is listed on the
NASDAQ Capital Market and trades under the ticker symbol
"PPHMP".
About Peregrine Pharmaceuticals,
Inc.Peregrine Pharmaceuticals, Inc. is a biopharmaceutical
company committed to improving the lives of patients by
manufacturing high quality pharmaceutical products through its
contract development and manufacturing organization (CDMO) services
and through advancing and licensing its investigational
immunotherapy and related products. Peregrine's in-house CDMO
services, including cGMP manufacturing and development
capabilities, are provided through its wholly-owned subsidiary Avid
Bioservices, Inc. (www.avidbio.com), which provides development and
biomanufacturing services for both Peregrine and third-party
customers. The company is also working to evaluate its lead
immunotherapy candidate, bavituximab, in combination with immune
stimulating therapies for the treatment of various cancers, and
developing its proprietary exosome technology for the detection and
monitoring of cancer. For more information, please visit
www.peregrineinc.com.
Contacts:
Jay Carlson
Peregrine Pharmaceuticals, Inc.
(800) 987-8256
info@peregrineinc.com
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Apr 2023 to Apr 2024